![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Intercell AG |
---|---|
Information provided by: | Intercell AG |
ClinicalTrials.gov Identifier: | NCT00602784 |
The objectives are
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis C |
Biological: IC41 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Parallel Assignment |
Official Title: | Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Intercell AG |
Study ID Numbers: | IC41-201 |
Study First Received: | January 4, 2008 |
Last Updated: | January 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00602784 |
Health Authority: | Austria: Bundesamt für Sicherheit im Gesundheitswesen; Germany: Paul-Ehrlich-Institut; Poland: Ministry of Health |
Virus Diseases Hepatitis Liver Diseases Digestive System Diseases |
Hepatitis, Chronic Hepatitis, Viral, Human Hepatitis C Hepatitis C, Chronic |
RNA Virus Infections Flaviviridae Infections |